PharmaKB logo
Company Reports
Company Reports
Drug Reports
Drug Reports
Disease Reports
Disease Reports
AboutPricing
Drug ReportsTartaric acid
Tartaric acid
Baros (tartaric acid) is a small molecule pharmaceutical. Tartaric acid was first approved as Baros on 1985-08-07.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Plot placeholder
Mock data
Subscribe for the real data
Commercial
Therapeutic Areas
No data
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Sodium bicarbonate
+
Tartaric acid
Tradename
Company
Number
Date
Products
BAROSMallinckrodtN-018509 DISCN1985-08-07
1 products
Hide discontinued
Labels
FDA
EMA
No data
Indications
FDA
EMA
No data
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
No data
HCPCS
No data
Clinical
Clinical Trials
26 clinical trials
View more details
Plot placeholder
Mock data
Subscribe for the real data
Indications Phases 4
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
OverweightD050177E66.3123
Weight lossD015431112
Delayed graft functionD05179911
Indications Phases 3
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Pancreatic neoplasmsD010190EFO_0003860C2511
Aphthous stomatitisD013281EFO_0003938K12.011
UlcerD014456MPATH_57911
Indications Phases 2
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
PinealomaD01087111
NeuroblastomaD009447EFO_000062111
Indications Phases 1
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Healthy volunteers/patients819
MalariaD008288EFO_0001068B5411
Falciparum malariaD016778EFO_0007444B5011
Indications Without Phase
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
ObesityD009765EFO_0001073E66.922
Failure to thriveD00518311
DwarfismD004392E34.3111
DyslipidemiasD05017111
Insulin resistanceD007333EFO_0002614E88.81911
Metabolic syndromeD024821EFO_0000195E88.81011
SyndromeD01357711
Ambulatory careD00055311
Covid-19D000086382U07.111
Sars-cov-2D00008640211
Show 5 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameTartaric acid
INN_
Description
2,3-dihydroxybutanedioic acid is a tetraric acid that is butanedioic acid substituted by hydroxy groups at positions 2 and 3. It has a role as a human xenobiotic metabolite and a plant metabolite. It is a conjugate acid of a 3-carboxy-2,3-dihydroxypropanoate.
Classification
Small molecule
Drug class
Image (chem structure or protein)Loading
Structure (InChI/SMILES or Protein Sequence)
O=C(O)[C@@H](O)[C@H](O)C(=O)O
Identifiers
PDB
CAS-ID147-71-7
RxCUI
ChEMBL IDCHEMBL1200861
ChEBI ID15672
PubChem CID875
DrugBankDB01694
UNII IDW4888I119H (ChemIDplus, GSRS)
Target
No data
Variants
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Plot placeholder
Mock data
Subscribe for the real data
Additional graphs summarizing 14,241 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Plot placeholder
Mock data
Subscribe for the real data
25 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use